Esophageal Cancer Systemic Therapy

Systemic therapy for esophageal cancer is selected according to disease stage and histology, with distinct regimens for neoadjuvant, adjuvant, definitive, and metastatic settings.

Neoadjuvant Therapy

For locally advanced esophageal cancer, neoadjuvant chemoradiotherapy (nCRT) yields higher R0 resection and pathologic complete response rates than neoadjuvant chemotherapy (nCT) alone, but without significant improvement in 3- or 5-year survival ^[3]A1a. Weight loss during neoadjuvant chemotherapy is critical: >5% weight loss independently predicts postoperative infectious complications (odds ratio 2.69, 95% CI 1.12-6.46) ^[7]B2b.

Adjuvant Therapy

After curative R0 resection for node-positive ESCC, adjuvant LV5FU2 and FOLFOX show comparable disease-free survival (HR 1.3, 95% CI 0.66-2.62) ^[8]B2b. Postoperative concurrent chemoradiotherapy for stage IIB-IVA disease achieves 1-year and 3-year overall survival rates of 91.6% and 57.0% ^[16]A1b.

Definitive and Unresectable Disease

For locally advanced unresectable thoracic ESCC, definitive chemoradiotherapy with cisplatin plus 5-fluorouracil remains standard. The TRIANgle trial is testing induction DCF followed by conversion surgery or CRT vs CRT alone ^[9]A1b. Salvage photodynamic therapy with talaporfin sodium achieves local complete response rates of 88-92% for local recurrence after CRT ^[19]C4.

Metastatic First-Line Therapy

First-line pembrolizumab plus chemotherapy (cisplatin 80 mg/m², 5-fluorouracil 800 mg/m²/day) significantly improves overall survival. In the Japanese subgroup of KEYNOTE-590, median OS was 17.7 months (95% CI 13.9-28.5) vs 11.7 months (95% CI 9.5-19.0) (HR 0.65, 95% CI 0.45-0.94); 60-month OS rates were 24.0% vs 8.5% ^[4]A1b. Benefit is most pronounced in patients with PD-L1 CPS≥10 (HR 0.52) and those with liver metastases (HR 0.31) ^[4]A1b. Cost-effectiveness analyses estimate an ICER of $176,479 per QALY, exceeding typical willingness-to-pay thresholds ^[5]A1b. Alternative first-line options include irinotecan /cisplatin (response rate 30%, median OS 8.8 months) ^[15]B2b.

Subsequent-Line Therapy

Second-line nivolumab monotherapy yields a response rate of 23%, median PFS 5.1 months, and median OS 14 months ^[10]B2b. The PI3K inhibitor BKM120 shows a disease control rate of 51.2% in pretreated advanced ESCC ^[13]B2b. Circulating tumor DNA monitoring identifies patients unlikely to benefit: high baseline ctDNA levels (top 20%) are associated with significantly shorter PFS (median 1.8 vs 4.6 months; HR 2.2) and OS (5.5 vs 9.9 months; HR 2.2) ^[12]B2b. Occurrence of immune-related adverse events independently predicts longer PFS ^[18]C4.

Oligometastatic Disease

Consensus definition: 1 organ with ≤3 metastases or 1 extra-regional lymph node station ^[2]A1a. Local treatment (metastasectomy or stereotactic radiotherapy) is associated with improved overall survival compared with systemic therapy alone (pooled adjusted HR 0.47, 95% CI 0.30-0.74) ^[2]A1a.

Pearl: In the metastatic setting, pembrolizumab plus chemotherapy provides a durable long-term survival tail (24% at 5 years), but cost-effectiveness remains a concern; patient selection using PD-L1 CPS and liver metastasis status optimizes the therapeutic index.

Building on the setting-based framework, concurrent chemoradiotherapy (CRT) is a cornerstone of treatment for both locally advanced unresectable disease and as neoadjuvant therapy prior to surgery.

Definitive Chemoradiotherapy

For patients with unresectable locally advanced esophageal cancer , definitive CRT is the standard of care ^[9]A1b. The standard radiation dose is 50 Gy in 25 fractions; a phase III trial comparing 60 Gy versus 50 Gy found no difference in local control or survival, but higher rates of severe pneumonitis with the higher dose ^[29]A1b. Concurrent chemotherapy typically consists of cisplatin 80 mg/m² on day 1 plus 5-fluorouracil 800 mg/m²/day continuous infusion on days 1-5 every 3 weeks ^[4]A1b, or weekly docetaxel 25 mg/m² plus cisplatin 25 mg/m² ^[29]A1b. For patients with renal impairment, nedaplatin may be substituted for cisplatin ^[31]B3b.

Neoadjuvant Chemoradiotherapy

In the neoadjuvant setting, CRT improves pathologic complete response (pCR) and R0 resection rates compared with chemotherapy alone, though without a significant improvement in 3- or 5-year overall survival ^[3]A1a. Over one-third of patients achieve pCR after neoadjuvant CRT ^[30]B3b. Weight loss >5% during neoadjuvant chemotherapy is an independent risk factor for postoperative infectious complications (odds ratio 2.69) ^[7]B2b. After neoadjuvant CRT and surgery, adjuvant chemotherapy may improve survival in patients with residual nodal disease (ypT+N+) ^[33]B3b.

Response Assessment

Early response assessment during CRT can guide treatment. Diffusion-weighted MRI (DWI) has a sensitivity of 0.82 and specificity of 0.81 for identifying response to concurrent CRT ^[22]B2a. Interim ¹⁸F-FDG PET during neoadjuvant CRT has prognostic value: a metabolic response predicts pathologic response with pooled sensitivity 0.80 and specificity 0.54 ^[25]B2a. However, routine use of PET to guide treatment decisions is not recommended ^[26]B2a.

Special Populations

In older adults (≥70 years) with ESCC, concurrent CRT is associated with lower treatment completion rates (adjusted risk ratio 0.86) and higher grade ≥3 toxicity (38.1% vs 17.8%) compared with radiotherapy alone ^[23]A1b. Careful patient selection is essential.

Pearl: The standard radiation dose for definitive CRT is 50 Gy; dose escalation to 60 Gy increases pneumonitis without improving survival ^[29]A1b.

Building on the concurrent chemoradiotherapy paradigm, the selection of systemic chemotherapy regimens, whether neoadjuvant, adjuvant, definitive, or palliative, is guided by histology, stage, and patient fitness. The evidence base spans decades of cisplatin -based combinations and, more recently, immunotherapy-chemotherapy backbones that have redefined first-line treatment for advanced disease.

Neoadjuvant Chemotherapy

For resectable locally advanced esophageal squamous cell carcinoma (ESCC), neoadjuvant chemotherapy (nCT) aims to downstage the tumor before surgery. The standard Japanese regimen is docetaxel , cisplatin, and 5-fluorouracil (DCF), as used in the JCOG1510 TRIANgLE trial ^[9]A1b. In patients ineligible for cisplatin due to renal or cardiac dysfunction or age ≥75 years, preoperative FOLFOX ( oxaliplatin , leucovorin, 5-fluorouracil) offers a manageable safety profile: among 35 such patients, the R0 resection rate was 87.1% and a pathologic complete response (pCR) was achieved in 16.1% ^[38]C4.

Weight loss during neoadjuvant therapy carries prognostic significance. In the OGSG1003 trial, patients with >5% weight loss during nCT had significantly more postoperative infectious complications (odds ratio 2.69, 95% CI 1.12-6.46) ^[7]B2b. Similarly, a 2.98% decrease in skeletal muscle index during neoadjuvant treatment correlated with worse 2-year survival ^[40]B3b.

A meta-analysis of three randomized trials comparing neoadjuvant chemoradiotherapy (nCRT) with nCT found that nCRT increased R0 resection and pCR rates but did not significantly improve 3- or 5-year progression-free or overall survival ^[3]A1a. Another meta-analysis of cisplatin-based adjuvant or neoadjuvant chemotherapy reported no significant survival benefit (odds ratio 0.96, 95% CI 0.75-1.22) ^[35]A1a.

Adjuvant Chemotherapy

For curatively resected, node-positive ESCC, a randomized phase II trial compared LV5FU2 (leucovorin, 5-fluorouracil) with FOLFOX (adding oxaliplatin). Median disease-free survival was 29.6 months with LV5FU2 versus 16.8 months with FOLFOX (p=0.428), and overall survival was not reached in either arm ^[8]B2b. Grade 3-4 neutropenia was more frequent with FOLFOX (20.0% vs 3.1%) ^[8]B2b. The addition of oxaliplatin did not improve efficacy.

Definitive Chemoradiotherapy Regimens

Definitive chemoradiotherapy (CRT) is standard for locally advanced unresectable esophageal cancer . The classic regimen is cisplatin 80 mg/m² on day 1 plus 5-fluorouracil 800 mg/m²/day continuous infusion on days 1-5, repeated every 3 weeks ^[4]A1b. An alternative oral regimen uses capecitabine 825 mg/m² twice daily on days 1-14 plus cisplatin 60 mg/m² on day 1, every 3 weeks, with concurrent radiotherapy (60 Gy); this achieved a complete response rate of 66.7% and 2-year overall survival of 70.7% ^[42]C4.

A Chinese phase III trial compared 60 Gy versus 50 Gy with concurrent weekly docetaxel 25 mg/m² and cisplatin 25 mg/m², followed by two cycles of consolidation chemotherapy. No significant difference in local/regional progression-free survival or overall survival was observed, but severe pneumonitis was higher in the 60 Gy group ^[29]A1b. 50 Gy remains the recommended radiation dose for definitive CRT ^[29]A1b.

Palliative Chemotherapy

For metastatic or unresectable disease, platinum-fluoropyrimidine doublets have been the historical backbone. Cisplatin plus 5-fluorouracil (FP) yields median overall survival of 6.6-9.5 months ^[4]A1b. Irinotecan 65 mg/m² plus cisplatin 30 mg/m² on days 1 and 8 every 21 days showed modest activity in ESCC: objective response rate 30.0%, median progression-free survival 4.5 months, and overall survival 8.8 months ^[15]B2b.

In China, the addition of Xiaoaiping to S-1 and cisplatin improved response rate (54.4% vs 34.5%), disease control rate (86.0% vs 69.1%), and median overall survival (12.93 vs 10.93 months) ^[17]A1b. For refractory gastroesophageal adenocarcinoma, nivolumab 240 mg plus irinotecan 120 mg/m² and 5-fluorouracil 2,000 mg/m² every 2 weeks yielded median progression-free survival of 7 months and overall survival of 13.3 months ^[41]B2b.

Immunotherapy-Chemotherapy Combinations

The addition of immune checkpoint inhibitors to chemotherapy has become a standard first-line option for advanced esophageal cancer. In the Japanese subgroup of KEYNOTE-590, pembrolizumab 200 mg every 3 weeks plus cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day (up to 35 cycles of pembrolizumab, ≤6 doses of cisplatin) was compared with placebo plus chemotherapy. After a median follow-up of 60.6 months, median overall survival was 17.7 months versus 11.7 months (HR 0.65, 95% CI 0.45-0.94); 60-month overall survival rates were 24.0% and 8.5% (NNT ≈ 7 to prevent one death at 5 years) ^[4]A1b. Median progression-free survival was 6.3 versus 6.0 months (HR 0.57, 95% CI 0.39-0.83), and objective response rate was 56.8% versus 38.8% ^[4]A1b. Benefit was observed across histologies and PD-L1 subgroups, with the greatest magnitude in patients with PD-L1 CPS≥10 (OS HR 0.52) ^[4]A1b.

Real-world data from a multi-institutional Japanese cohort confirmed a response rate of 58% and median progression-free survival of 9.7 months with immune checkpoint inhibitor combination therapy ^[39]C4. The occurrence of immune-related adverse events (irAEs) was independently associated with improved progression-free survival (HR for progression 0.003) ^[18]C4.

Despite clinical efficacy, cost-effectiveness analyses from the Japanese healthcare payer perspective estimate an incremental cost-effectiveness ratio of $176,479 per QALY for pembrolizumab plus chemotherapy, exceeding the willingness-to-pay threshold of $50,000-100,000/QALY ^[5]A1b. Even in the PD-L1 CPS≥10 subgroup, the ICER was $126,862/QALY ^[5]A1b.

Controversies and Guideline Disagreement

Pearl: For patients with locally advanced esophageal cancer, neoadjuvant chemoradiotherapy (CROSS regimen) remains the preferred approach for resectable disease, while definitive chemoradiotherapy with 50 Gy is standard for unresectable disease; the addition of pembrolizumab to cisplatin/ 5-FU improves long-term survival in the metastatic setting, though cost-effectiveness remains a concern in Japan.

The addition of immune checkpoint inhibitors to platinum-fluoropyrimidine doublets has redefined first-line treatment for advanced esophageal cancer , with multiple PD-1 inhibitors now demonstrating survival benefits across histologic subtypes. This section reviews the evidence for approved and emerging immunotherapies, targeted agents, and the biomarkers that guide their use.

PD-1/PD-L1 Inhibitors in First-Line Treatment

Pembrolizumab is the most extensively studied PD-1 inhibitor in this setting. In the phase 3 KEYNOTE-590 trial, pembrolizumab 200 mg every 3 weeks plus cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day significantly improved overall survival (OS) versus chemotherapy alone in the global population (HR 0.72; 95% CI 0.62-0.84) ^[4]A1b. Five-year OS rates were 10.6% with pembrolizumab plus chemotherapy versus 3.0% with chemotherapy alone ^[4]A1b. In the Japanese subgroup (n=141), median OS was 17.7 months (95% CI 13.9-28.5) versus 11.7 months (95% CI 9.5-19.0) (HR 0.65; 95% CI 0.45-0.94), with 60-month OS rates of 24.0% and 8.5% ^[4]A1b. Progression-free survival (PFS) was also improved (HR 0.57; 95% CI 0.39-0.83), and the objective response rate (ORR) was 56.8% versus 38.8% ^[4]A1b. Grade 3-4 treatment-related adverse events occurred in 74.3% of pembrolizumab-treated patients versus 59.7% in the placebo group ^[4]A1b.

Nivolumab plus chemotherapy has shown similar efficacy. In CheckMate 648, first-line nivolumab plus chemotherapy improved OS versus chemotherapy alone in advanced ESCC (HR 0.77; 95% CI 0.65-0.92) at 61-month follow-up ^[4]A1b. The Japanese subgroup reported an OS HR of 0.81 ^[4]A1b.

Serplulimab, a humanized anti-PD-1 IgG4 antibody, was evaluated in the phase 3 ASTRUM-007 trial. In patients with PD-L1-positive ESCC (CPS ≥1), serplulimab plus chemotherapy improved median OS versus placebo plus chemotherapy (15.3 months vs 11.8 months; HR 0.68; 95% CI 0.53-0.87) ^[44]A1a. A matching-adjusted indirect comparison (MAIC) found serplulimab comparable to other PD-1 inhibitors for OS (pooled HR 0.98; 95% CI 0.87-1.11) and showed a significant PFS benefit versus nivolumab (adjusted HR 0.56; 95% CI 0.33-0.96) ^[44]A1a.

Multiple other PD-1 inhibitors have demonstrated efficacy in first-line ESCC, including camrelizumab (ESCORT-1st: OS HR 0.70), tislelizumab (RATIONALE-306: OS HR 0.66), toripalimab (JUPITER-06: OS HR 0.58), sugemalimab (GEMSTONE-304: OS HR 0.68), and sintilimab (ORIENT-15: OS HR 0.63) ^[44]A1a. Table 1 summarizes the key phase 3 trials.

Table 1: Key phase 3 trials of first-line PD-1 inhibitors plus chemotherapy in advanced esophageal cancer. Data from ^[44]A1a.

Second-Line and Later-Line Immunotherapy

Pembrolizumab monotherapy is approved for patients with advanced ESCC and PD-L1 CPS ≥10 after one prior systemic therapy, based on KEYNOTE-180 and KEYNOTE-181 ^[45]B2b. In KEYNOTE-181, pembrolizumab improved median OS versus chemotherapy in the CPS ≥10 population (9.3 months vs 6.7 months; HR 0.69; 95% CI 0.52-0.93), with grade 3-5 treatment-related adverse events in 18% versus 41% ^[45]B2b. For patients with MSI-H or dMMR tumors, pembrolizumab is approved across solid tumor types, with an ORR of 53% reported in a phase 2 study ^[45]B2b. Nivolumab has also shown activity in pretreated esophageal cancer, with an ORR of 17% and median OS of 10.8 months in a phase 2 study ^[45]B2b.

Predictive Biomarkers

PD-L1 combined positive score (CPS) is the most important predictive biomarker for PD-1 inhibitor efficacy in esophageal cancer ^[47]D5. The benefit of immunotherapy is most pronounced in patients with CPS ≥10, though clinically meaningful improvements are also seen in lower-expression groups ^[4]A1b. Standardized testing using validated assays (e.g., PD-L1 IHC 22C3 pharmDx) is essential for patient selection ^[47]D5. Microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) identifies a smaller subset (~1-2% of esophageal cancers) with high response rates to PD-1 inhibitors ^[45]B2b. Circulating tumor DNA (ctDNA) is an emerging biomarker: high baseline levels and early increases identify patients unlikely to benefit from treatment, though prospective validation is needed ^[12]B2b.

Targeted Therapy

Unlike in gastric and gastroesophageal junction adenocarcinoma, where trastuzumab is standard for HER2-positive disease, no targeted agent has demonstrated a survival benefit when added to chemotherapy in the first-line treatment of esophageal cancer. Anti-VEGF agents (e.g., bevacizumab ) and anti-EGFR inhibitors have not improved outcomes in phase 3 trials ^[49]D5. The combination of trifluridine-tipiracil plus bevacizumab has shown activity in refractory gastroesophageal adenocarcinoma, but its role in pure esophageal cancer remains undefined ^[12]B2b.

Emerging Agents and Future Directions

Serplulimab has been approved in China for first-line PD-L1-positive ESCC, with a favorable benefit-risk profile compared to other PD-1 inhibitors in indirect analyses ^[44]A1a. Body composition may influence ICI outcomes: a high waist circumference was associated with better PFS in patients receiving nivolumab or pembrolizumab-based therapy (multivariable HR 0.56 per 5-cm increase; 95% CI 0.33-0.94) ^[50]D5. Ongoing studies are evaluating PD-1 inhibitors in combination with CTLA-4 blockade (nivolumab plus ipilimumab ), novel immunomodulatory agents, and in perioperative settings ^[45]B2b. Adoptive T cell therapy and cancer vaccines remain investigational ^[48]D5.

Pearl: For first-line treatment of advanced esophageal cancer, pembrolizumab plus chemotherapy provides a 5-year OS of 24% in Japanese patients and 10.6% globally; PD-L1 CPS ≥10 identifies the subgroup with greatest benefit, but the survival advantage extends across histologies and PD-L1 levels ^[4]A1b.

Having reviewed the efficacy of targeted and immune therapies, the clinician must also anticipate and manage their associated toxicities. Systemic therapy for esophageal cancer , whether chemotherapy, immunotherapy, or chemoradiation, carries a predictable burden of adverse events that require active surveillance and prompt intervention. The spectrum ranges from common chemotherapy-related toxicities (neutropenia, neuropathy, thrombosis) to immune-related adverse events (irAEs) unique to checkpoint inhibitors, and radiation-induced organ damage when radiotherapy is combined.

Immune-Related Adverse Events

Immune checkpoint inhibitors (ICIs) activate T-cell responses that can attack normal tissues. In real-world cohorts, grade 3 or higher irAEs occurred in 14% of patients receiving second-line nivolumab monotherapy and in 13% of those receiving ICI combination therapy (ICI + chemotherapy or ICI + ICI) ^{[10]B2b[39]C4}. One treatment-related death from cholangitis was reported in the combination therapy group ^[39]C4. Importantly, the occurrence of irAEs is independently associated with improved progression-free survival (PFS) and overall survival (OS). In a retrospective study of 100 patients, those who developed any irAE had significantly longer PFS and OS compared with those who did not (P < 0.001 and P = 0.020, respectively), and irAE occurrence was an independent predictor of longer PFS on multivariate analysis (P = 0.003) ^[18]C4. This paradoxical relationship suggests that irAEs may serve as a surrogate marker for immune activation and treatment benefit.

Management of irAEs follows established guidelines: low-grade events (grade 1-2) often resolve with symptomatic treatment and temporary ICI hold; grade 3 or higher events typically require systemic corticosteroids (e.g., prednisone 1-2 mg/kg/day) and permanent discontinuation of the offending agent. Specific organ involvement (colitis, pneumonitis, hepatitis, dermatitis) dictates additional workup and tailored therapy.

Chemotherapy-Related Toxicities

Although the provided evidence does not report specific rates for chemotherapy-related toxicities, standard regimens (platinum/fluoropyrimidine, taxanes) are associated with myelosuppression, peripheral neuropathy , nausea, and venous thromboembolism. Supportive care includes growth factor support for neutropenia, dose reductions or delays for neuropathy, antiemetic prophylaxis, and anticoagulation for thrombosis. Close monitoring of blood counts and renal function is essential.

Radiation-Related Toxicities

When systemic therapy is combined with definitive radiotherapy, radiation-induced toxicities are common. In a multi-center study of T1-2N0M0 esophageal squamous cell carcinoma treated with definitive radiotherapy (median dose 60 Gy), the incidence of radiation pneumonitis was 14.80% (29/196) and radiation esophagitis was 65.82% (129/196) ^[52]B3b. The vast majority of these events were grade 1-2; no grade 4 toxicity was observed ^[52]B3b. Management of radiation esophagitis includes oral analgesics, topical anesthetics, dietary modifications (soft, bland foods), and proton pump inhibitors for reflux. Radiation pneumonitis is treated with corticosteroids and supportive care; severe cases may require oxygen and hospitalization.

Prognostic Factors and Supportive Care

Beyond toxicity management, baseline patient factors influence tolerance and outcomes. Myosteatosis (low skeletal muscle radiodensity) without systemic inflammation (neutrophil-to-lymphocyte ratio ≤ 2.8) was independently associated with favorable PFS and OS in patients receiving definitive chemoradiotherapy (HR for progression 0.47, 95% CI 0.26-0.85; HR for death 0.39, 95% CI 0.21-0.72) ^[51]B3b. Conversely, elevated C-reactive protein and poor performance status predict worse survival in patients receiving ICI therapy ^{[10]B2b[39]C4}. These factors should inform pre-treatment risk stratification and supportive care planning.

Pearl: The occurrence of immune-related adverse events, while requiring active management, is paradoxically associated with improved progression-free survival in patients receiving ICI therapy for esophageal cancer; this association should not deter clinicians from treating toxicities but may inform prognostic discussions ^[18]C4.

The toxicity profile of systemic therapy is amplified in patients with baseline vulnerabilities, making performance status, age, organ function, and nutritional reserve critical determinants of treatment selection and outcomes.

Performance Status and Frailty

Performance status (PS) is one of the strongest prognostic factors across all treatment settings. In second-line nivolumab monotherapy, PS was a significant predictor of overall survival ^[10]B2b. Among patients receiving immune-checkpoint inhibitor combination therapy, good PS and low C-reactive protein levels identified those most likely to benefit ^[39]C4. Poor PS ( ECOG 2-4) independently increased mortality (HR 1.38) and predicted poor response to concurrent chemoradiotherapy ^[60]D5. In the trimodality versus bimodality decision, worse PS was associated with receipt of bimodality therapy (definitive chemoradiation without surgery), which carried significantly lower survival (3-year OS 18% vs 62%) ^[56]B3b. Sarcopenia, measured by skeletal muscle index (SMI) at L3, increases postoperative complications:

• Overall morbidity: RR 1.16 (95% CI 1.01-1.33)
• Respiratory complications: RR 1.64 (95% CI 1.21-2.22)
• Anastomotic leaks: RR 1.39 (95% CI 1.10-1.76) Preoperative nutritional optimization and closer postoperative vigilance are warranted in sarcopenic patients ^[53]B2a.

Elderly Patients

Older age alone should not preclude aggressive therapy, but age-adjusted comorbidity burden often drives treatment selection. In a real-world cohort, patients receiving bimodality therapy had higher age-adjusted comorbidity indices and were more likely to hold chemotherapy cycles ^[56]B3b. For patients with cervical lymph node metastasis, those receiving radiotherapy alone were the oldest (mean age 74 years) and had the poorest survival (median OS 7 months) ^[27]B2b. Definitive chemoradiotherapy remains an option for fit elderly patients, though careful dose selection and supportive care are essential.

Renal Impairment

Cisplatin -based regimens, common in esophageal cancer , require adequate renal function. In a randomized trial of Xiaoaiping plus S-1/cisplatin, renal impairment was reported as an adverse event in both arms ^[17]A1b. No specific dose modifications are provided in the available evidence; clinicians should follow standard cisplatin renal dosing guidelines and consider carboplatin substitution when creatinine clearance is <60 mL/min.

HIV/AIDS and Immunocompromised Patients

No dedicated studies in the provided evidence address systemic therapy for esophageal cancer in patients with HIV/AIDS or other immunocompromised states. Immune checkpoint inhibitors carry a theoretical risk of immune-related adverse events in the setting of preexisting immune dysregulation. Multidisciplinary management with infectious disease consultation is recommended.

Cervical Lymph Node Metastasis

Cervical lymph node metastasis (CLNM) represents a conceptual border zone between locoregional and distant disease. In a Dutch nationwide cohort, management was highly heterogeneous. Neoadjuvant therapy followed by surgery was associated with longer survival compared with definitive chemoradiotherapy (HR 0.56, 95% CI 0.34-0.91; median OS 24 vs 18 months; 3-year OS 38% vs 21%) ^[27]B2b. Higher cN stage and poorer PS were independently associated with worse survival. Surgery may be considered in carefully selected patients with CLNM as part of multimodality treatment.

Pearl: Performance status (ECOG ≥2) is the single most powerful predictor of treatment failure and mortality across all systemic therapy settings; objective assessment of sarcopenia via SMI can further refine perioperative risk stratification.

Part of the Esophageal Cancer family. Cross-cutting management is split across dedicated child pages:

• Esophageal Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Esophageal Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
• Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
• Esophageal Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
• Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.